Page last updated: 2024-10-25

cilostazol and Reperfusion Injury

cilostazol has been researched along with Reperfusion Injury in 33 studies

Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.

Research Excerpts

ExcerptRelevanceReference
"Cilostazol significantly improves ACD, in addition to attenuating exercise-induced ischaemia-reperfusion injury, in PAD patients."9.14The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. ( Badger, SA; Lee, B; Makar, RR; McEneny, J; O'Donnell, ME; Sharif, MA; Soong, CV; Young, IS, 2009)
"This study aims to determine the protective effect of cilostazol on myocardium in obese Wistar rats with induced ischemia-reperfusion injury (IRI)."8.31Effects of Cilostazol on the Myocardium in an Obese Wistar Rat Model of Ischemia-Reperfusion Injury. ( Demir, T; Ilal Mert, FT; Sahin, M; Sarac, F, 2023)
"To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models."8.12Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. ( Baytaroglu, C; Sahin, M; Sevgili, E, 2022)
"The aim of this study was to evaluate the pretreatment effect of cilostazol on spinal cord ischemia-reperfusion injury."7.81Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits. ( Alpay, MF; Cakir, O; Colak, N; Erdamar, H; Haltas, H; Namuslu, M; Nazli, Y; Nuri Aksoy, O; Olgun Akkaya, I, 2015)
" Cilostazol pre-treatment protected against cold hepatic ischemia-reperfusion injury by preventing hepatocellular disintegration, ICAM-1-associated endothelial inflammation, and apoptotic death."7.81Preconditioning by cilostazol protects against cold hepatic ischemia-reperfusion injury. ( Keppler, U; Menger, MD; Moussavian, MR; Müller, S; Scheuer, C; Schilling, MK; Strowitzki, MJ; von Heesen, M, 2015)
"To evaluate effects of ischemic preconditioning and Cilostazol on muscle ischemia-reperfusion injury."7.80Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats. ( Frias Neto, CA; Koike, MK; Montero, EF; Saad, KR; Saad, PF, 2014)
"Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice."7.78Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012)
"Acetylcholine-and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group, and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment."7.78The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. ( Capellini, VK; Celotto, AC; Evora, PR; Joviliano, EE; Piccinato, CE; Santos, MR, 2012)
"Cilostazol had no protective effect on the kidney and the skeletal striated muscle in rats submitted to acute ischemia and reperfusion in this model."7.78Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. ( Capelozzi, VL; Francisco Neto, A; Moreira Neto, AA; Parra-Cuentas, ER; Rodrigues, OR; Schmidt Júnior, AF; Souza Júnior, SS, 2012)
" The present study examined whether or not cilostazol reduces the myocardial infarct size, and investigated its mechanism in a rabbit model of myocardial infarction."7.77Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. ( Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y, 2011)
"Treatment with cilostazol significantly improved pathological findings associated with liver I/R injury and increased survival rate compared to that in controls."5.46Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury. ( Abe, Y; Fujii, T; Fujimura, N; Hibi, T; Itano, O; Kitagawa, Y; Kitago, M; Masugi, Y; Matsubara, K; Obara, H; Sakamoto, M; Shinoda, M; Tanabe, M; Yagi, H, 2017)
"Oral treatment with cilostazol (30 mg/kg) significantly increased plasma leakage."5.36The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. ( Hattori, K; Kajimura, M; Morikawa, T; Suematsu, M, 2010)
"Cilostazol significantly improves ACD, in addition to attenuating exercise-induced ischaemia-reperfusion injury, in PAD patients."5.14The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. ( Badger, SA; Lee, B; Makar, RR; McEneny, J; O'Donnell, ME; Sharif, MA; Soong, CV; Young, IS, 2009)
"This study aims to determine the protective effect of cilostazol on myocardium in obese Wistar rats with induced ischemia-reperfusion injury (IRI)."4.31Effects of Cilostazol on the Myocardium in an Obese Wistar Rat Model of Ischemia-Reperfusion Injury. ( Demir, T; Ilal Mert, FT; Sahin, M; Sarac, F, 2023)
"To clarify the potential protective role of cilostazol on rat myocardial cells with ischemia-reperfusion injury (IRI) models."4.12Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model. ( Baytaroglu, C; Sahin, M; Sevgili, E, 2022)
"The aim of this study was to evaluate the pretreatment effect of cilostazol on spinal cord ischemia-reperfusion injury."3.81Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits. ( Alpay, MF; Cakir, O; Colak, N; Erdamar, H; Haltas, H; Namuslu, M; Nazli, Y; Nuri Aksoy, O; Olgun Akkaya, I, 2015)
" Cilostazol pre-treatment protected against cold hepatic ischemia-reperfusion injury by preventing hepatocellular disintegration, ICAM-1-associated endothelial inflammation, and apoptotic death."3.81Preconditioning by cilostazol protects against cold hepatic ischemia-reperfusion injury. ( Keppler, U; Menger, MD; Moussavian, MR; Müller, S; Scheuer, C; Schilling, MK; Strowitzki, MJ; von Heesen, M, 2015)
"We investigated the effects of cilostazol, a selective inhibitor of phosphodiesterase 3, on blood-brain barrier (BBB) integrity against ischemia-reperfusion injury enhanced by advanced glycation endproducts (AGEs)."3.80Cilostazol attenuates ischemia-reperfusion-induced blood-brain barrier dysfunction enhanced by advanced glycation endproducts via transforming growth factor-β1 signaling. ( Deli, MA; Hayashi, K; Nagata, I; Nakagawa, S; Niwa, M; So, G; Takeshita, T; Tanaka, K; Tatsumi, R, 2014)
"To evaluate effects of ischemic preconditioning and Cilostazol on muscle ischemia-reperfusion injury."3.80Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats. ( Frias Neto, CA; Koike, MK; Montero, EF; Saad, KR; Saad, PF, 2014)
"Treatment with cilostazol for 7 days before ischemia significantly suppressed the risk and severity of cerebral hemorrhage after injection of tissue-type plasminogen activator, although treatment with aspirin had no such protective effect compared with nontreated mice."3.78Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. ( Kasahara, Y; Matsuyama, T; Nakagomi, T; Stern, D; Taguchi, A, 2012)
"Acetylcholine-and A23187-induced relaxation was reduced in the Ischemia/Reperfusion 120/90 group, and treatment with cilostazol partially prevented this ischemia/reperfusion-induced endothelium impairment."3.78The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway. ( Capellini, VK; Celotto, AC; Evora, PR; Joviliano, EE; Piccinato, CE; Santos, MR, 2012)
"Cilostazol had no protective effect on the kidney and the skeletal striated muscle in rats submitted to acute ischemia and reperfusion in this model."3.78Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs. ( Capelozzi, VL; Francisco Neto, A; Moreira Neto, AA; Parra-Cuentas, ER; Rodrigues, OR; Schmidt Júnior, AF; Souza Júnior, SS, 2012)
" The present study examined whether or not cilostazol reduces the myocardial infarct size, and investigated its mechanism in a rabbit model of myocardial infarction."3.77Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. ( Aoyama, T; Bai, Y; Iwasa, M; Minatoguchi, S; Murakami, H; Nishigaki, K; Sumi, S; Takemura, G; Uno, B; Ushikoshi, H; Yamada, Y, 2011)
"Cilostazol (CLZ) is a selective phosphodiesterase (PDE) 3A inhibitor used for treatment of intermittent claudication."1.62Dose dependent effect of cilostazol in induced testicular ischemia reperfusion via modulation of HIF/VEGF and cAMP/SIRT1 pathways. ( Ahmed Ibrahim, R; Refaie, MMM; Shehata, S, 2021)
"Treatment with cilostazol significantly improved pathological findings associated with liver I/R injury and increased survival rate compared to that in controls."1.46Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury. ( Abe, Y; Fujii, T; Fujimura, N; Hibi, T; Itano, O; Kitagawa, Y; Kitago, M; Masugi, Y; Matsubara, K; Obara, H; Sakamoto, M; Shinoda, M; Tanabe, M; Yagi, H, 2017)
"Cilostazol(CTL) is a phosphodiesterase inhibitor, which has been widely used as anti-platelet agent."1.43Neuroprotection of Cilostazol against ischemia/reperfusion-induced cognitive deficits through inhibiting JNK3/caspase-3 by enhancing Akt1. ( Li, M; Liu, F; Liu, P; Ma, JY; Mei, XY; Miu, JC; Qi, DS; Qu, R; Tao, JH; Wang, M; Zhang, F; Zhang, LQ; Zhang, SC, 2016)
"Cilostazol is a phosphodiesterase inhibitor that has anti-inflammatory potential in addition to vasodilator and antiplatelet effects."1.40Effects of cilostazol on oxidative stress, systemic cytokine release, and spinal cord injury in a rat model of transient aortic occlusion. ( Basoglu, H; Cetin, NK; Discigil, B; Kurtoglu, T; Ozkisacik, EA; Tataroglu, C; Yenisey, C, 2014)
"Pretreatment with cilostazol or pioglitazone provided significant protection against the I/R-induced renal injury as manifested by the attenuated serum levels of creatinine, blood urea nitrogen and cystatin C."1.40Cilostazol renoprotective effect: modulation of PPAR-γ, NGAL, KIM-1 and IL-18 underlies its novel effect in a model of ischemia-reperfusion. ( Abdallah, DM; El-Abhar, HS; Ragab, D, 2014)
"Oral treatment with cilostazol (30 mg/kg) significantly increased plasma leakage."1.36The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. ( Hattori, K; Kajimura, M; Morikawa, T; Suematsu, M, 2010)
"Cilostazol inhibits the increase in compartment pressure central to the development of the compartment syndrome."1.30Selective type III phosphodiesterase inhibition prevents elevated compartment pressure after ischemia/reperfusion injury. ( Cunningham, L; Hakaim, AG; Hoover, K; White, JL, 1999)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (3.03)18.2507
2000's6 (18.18)29.6817
2010's20 (60.61)24.3611
2020's6 (18.18)2.80

Authors

AuthorsStudies
Refaie, MMM2
Ahmed Ibrahim, R1
Shehata, S2
Sahin, M2
Baytaroglu, C1
Sevgili, E1
El-Hussieny, M1
Demir, T1
Ilal Mert, FT1
Sarac, F1
Gülaştı, ÖF1
Yavuz, Ş1
Arıkan, AA1
Eraldemir, FC1
Özbudak, E1
Şahin, D1
Kır, HM1
Gendy, AM1
Amin, MM1
Al-Mokaddem, AK1
Abd Ellah, MF1
Inan, B1
Sönmez Ergün, S1
Nurten, A1
Küçükgergin, C1
Zengin Türkmen, A1
Seçkin, Ş1
Erkalp, K1
Ziyade, S1
Fujii, T1
Obara, H1
Matsubara, K1
Fujimura, N1
Yagi, H1
Hibi, T1
Abe, Y1
Kitago, M1
Shinoda, M1
Itano, O1
Tanabe, M1
Masugi, Y1
Sakamoto, M1
Kitagawa, Y1
Nan, D1
Jin, H1
Deng, J1
Yu, W1
Liu, R1
Sun, W1
Huang, Y1
Souza Júnior, SS2
Moreira Neto, AA2
Schmidt Júnior, AF2
Lemos, JB1
Rodrigues, OR2
Takeshita, T1
Nakagawa, S1
Tatsumi, R1
So, G1
Hayashi, K1
Tanaka, K1
Deli, MA1
Nagata, I1
Niwa, M1
Kurtoglu, T1
Basoglu, H1
Ozkisacik, EA1
Cetin, NK1
Tataroglu, C1
Yenisey, C1
Discigil, B1
Ragab, D1
Abdallah, DM1
El-Abhar, HS1
Frias Neto, CA1
Koike, MK1
Saad, KR1
Saad, PF1
Montero, EF1
Nazli, Y1
Colak, N1
Namuslu, M1
Erdamar, H1
Haltas, H1
Alpay, MF1
Nuri Aksoy, O1
Olgun Akkaya, I1
Cakir, O1
von Heesen, M1
Müller, S1
Keppler, U1
Strowitzki, MJ1
Scheuer, C1
Schilling, MK1
Menger, MD1
Moussavian, MR1
Joe, Y1
Zheng, M1
Kim, HJ1
Uddin, MJ1
Kim, SK1
Chen, Y1
Park, J1
Cho, GJ1
Ryter, SW1
Chung, HT1
Nagai, N1
Yoshioka, C1
Ito, Y2
Funakami, Y1
Nishikawa, H1
Kawabata, A1
Qi, DS1
Tao, JH1
Zhang, LQ1
Li, M1
Wang, M1
Qu, R1
Zhang, SC1
Liu, P1
Liu, F1
Miu, JC1
Ma, JY1
Mei, XY1
Zhang, F1
O'Donnell, ME1
Badger, SA1
Sharif, MA1
Makar, RR1
McEneny, J1
Young, IS1
Lee, B1
Soong, CV1
Morikawa, T1
Hattori, K1
Kajimura, M1
Suematsu, M1
Sahin, MA1
Onan, B1
Guler, A1
Oztas, E1
Uysal, B1
Arslan, S1
Demirkilic, U1
Tatar, H1
Bai, Y1
Murakami, H1
Iwasa, M1
Sumi, S1
Yamada, Y1
Ushikoshi, H1
Aoyama, T1
Nishigaki, K1
Takemura, G1
Uno, B1
Minatoguchi, S1
Reis, F1
Kasahara, Y1
Nakagomi, T1
Matsuyama, T1
Stern, D1
Taguchi, A1
Santos, MR1
Celotto, AC1
Capellini, VK1
Evora, PR1
Piccinato, CE1
Joviliano, EE1
Capelozzi, VL1
Parra-Cuentas, ER1
Francisco Neto, A1
Lee, JH2
Kim, KY2
Lee, YK1
Park, SY1
Kim, CD1
Lee, WS1
Rhim, BY1
Hong, KW2
Iba, T2
Kidokoro, A1
Fukunaga, M1
Takuhiro, K1
Ouchi, M1
Manickavasagam, S1
Ye, Y1
Lin, Y1
Perez-Polo, RJ1
Huang, MH1
Lui, CY1
Hughes, MG1
McAdoo, DJ1
Uretsky, BF1
Birnbaum, Y1
Hakaim, AG1
Cunningham, L1
White, JL1
Hoover, K1
Choi, JM1
Shin, HK1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of the Effect of Cilostazol on the Clinical Outcomes of Rheumatoid Arthritis Patients[NCT05671497]Phase 2/Phase 370 participants (Anticipated)Interventional2022-11-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for cilostazol and Reperfusion Injury

ArticleYear
[Pretreatment with cilostazol protects against the vascular endothelial damage after ischemia/reperfusion].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2008, Volume: 131, Issue:2

    Topics: Animals; Aspirin; Cilostazol; Dipyridamole; Endothelial Cells; Ischemic Preconditioning; Mice; Phosp

2008

Trials

1 trial available for cilostazol and Reperfusion Injury

ArticleYear
The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2009, Volume: 37, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Albuminuria; alpha-Tocopherol; Ascorbate Oxidase; beta Carotene; C-R

2009

Other Studies

31 other studies available for cilostazol and Reperfusion Injury

ArticleYear
Dose dependent effect of cilostazol in induced testicular ischemia reperfusion via modulation of HIF/VEGF and cAMP/SIRT1 pathways.
    International immunopharmacology, 2021, Volume: 101, Issue:Pt A

    Topics: Animals; Blotting, Western; Cilostazol; Cyclic AMP; Dose-Response Relationship, Drug; Interleukin-1b

2021
Cardioprotective Effect of Cilostazol on Ischemia-Reperfusion Injury Model.
    Brazilian journal of cardiovascular surgery, 2022, 12-01, Volume: 37, Issue:6

    Topics: Adenosine Triphosphate; Animals; Cilostazol; Disease Models, Animal; Ischemia; Rats; Rats, Wistar; R

2022
TLR4/NF-κB/TNFα and cAMP/SIRT1 signaling cascade involved in mediating the dose-dependent effect of cilostazol in ovarian ischemia reperfusion-induced injury.
    Immunopharmacology and immunotoxicology, 2022, Volume: 44, Issue:3

    Topics: Animals; Antioxidants; Cilostazol; NF-kappa B; Rats; Reperfusion; Reperfusion Injury; Sirtuin 1; Tol

2022
Effects of Cilostazol on the Myocardium in an Obese Wistar Rat Model of Ischemia-Reperfusion Injury.
    Current vascular pharmacology, 2023, Volume: 21, Issue:4

    Topics: Animals; Cilostazol; Myocardium; Plasminogen Activator Inhibitor 1; Rats; Rats, Wistar; Reperfusion

2023
Comparison of Cilostazol and Naftidrofuryl in an Experimental Acute Ischemia-Reperfusion Model.
    Vascular and endovascular surgery, 2021, Volume: 55, Issue:1

    Topics: Animals; Antioxidants; Biomarkers; Brain; Cilostazol; Disease Models, Animal; Kidney; Liver; Male; M

2021
Cilostazol mitigates mesenteric ischemia/reperfusion-induced lung lesion: Contribution of PPAR-γ, NF-κB, and STAT3 crosstalk.
    Life sciences, 2021, Feb-01, Volume: 266

    Topics: Animals; Bronchodilator Agents; Cilostazol; Gene Expression Regulation; Lung Diseases; Male; Mesente

2021
Effects of Cilostazol and Diltiazem Hydrochloride on Ischemia-Reperfusion Injury in a Rat Hindlimb Model.
    The heart surgery forum, 2017, Apr-29, Volume: 20, Issue:2

    Topics: Animals; Calcium Channel Blockers; Cilostazol; Diltiazem; Disease Models, Animal; Drug Therapy, Comb

2017
Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury.
    The Journal of surgical research, 2017, 06-01, Volume: 213

    Topics: Administration, Oral; Animals; Biomarkers; Cilostazol; Drug Administration Schedule; Liver; Male; Ph

2017
Cilostazol ameliorates ischemia/reperfusion-induced tight junction disruption in brain endothelial cells by inhibiting endoplasmic reticulum stress.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:9

    Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cilostazol; Cyclic AMP; Drug Evaluation, Preclinical;

2019
Biochemical study of the effects of cilostazol in rats subjected to acute ischemia and reperfusion of hind limbs.
    Acta cirurgica brasileira, 2013, Volume: 28, Issue:5

    Topics: Animals; Cilostazol; Creatinine; Disease Models, Animal; Hindlimb; Male; Myoglobin; Platelet Aggrega

2013
Cilostazol attenuates ischemia-reperfusion-induced blood-brain barrier dysfunction enhanced by advanced glycation endproducts via transforming growth factor-β1 signaling.
    Molecular and cellular neurosciences, 2014, Volume: 60

    Topics: Animals; Astrocytes; Blood-Brain Barrier; Capillary Permeability; Cell Hypoxia; Cells, Cultured; Cil

2014
Effects of cilostazol on oxidative stress, systemic cytokine release, and spinal cord injury in a rat model of transient aortic occlusion.
    Annals of vascular surgery, 2014, Volume: 28, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Aorta, Abdominal; Biomarkers; Cell Survival; Cilost

2014
Cilostazol renoprotective effect: modulation of PPAR-γ, NGAL, KIM-1 and IL-18 underlies its novel effect in a model of ischemia-reperfusion.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Acute Kidney Injury; Acute-Phase Proteins; Animals; Blood Urea Nitrogen; Caspase 1; Cell Adhesion Mo

2014
Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats.
    Acta cirurgica brasileira, 2014, Volume: 29 Suppl 3

    Topics: Animals; Cilostazol; Hindlimb; Ischemia; Ischemic Preconditioning; Male; Models, Animal; Muscle Fibe

2014
Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits.
    Journal of cardiothoracic and vascular anesthesia, 2015, Volume: 29, Issue:2

    Topics: Animals; Cilostazol; Disease Models, Animal; Phosphodiesterase 3 Inhibitors; Prospective Studies; Ra

2015
Preconditioning by cilostazol protects against cold hepatic ischemia-reperfusion injury.
    Annals of transplantation, 2015, Mar-26, Volume: 20

    Topics: Animals; Apoptosis; Cilostazol; Endothelial Cells; Female; Intercellular Adhesion Molecule-1; Ischem

2015
Cilostazol attenuates murine hepatic ischemia and reperfusion injury via heme oxygenase-dependent activation of mitochondrial biogenesis.
    American journal of physiology. Gastrointestinal and liver physiology, 2015, Jul-01, Volume: 309, Issue:1

    Topics: Animals; Cilostazol; Cytoprotection; Disease Models, Animal; DNA-Binding Proteins; Gene Expression R

2015
Intravenous Administration of Cilostazol Nanoparticles Ameliorates Acute Ischemic Stroke in a Cerebral Ischemia/Reperfusion-Induced Injury Model.
    International journal of molecular sciences, 2015, Dec-09, Volume: 16, Issue:12

    Topics: Administration, Intravenous; Animals; Blood Pressure; Brain; Cilostazol; Infarction, Middle Cerebral

2015
Neuroprotection of Cilostazol against ischemia/reperfusion-induced cognitive deficits through inhibiting JNK3/caspase-3 by enhancing Akt1.
    Brain research, 2016, 12-15, Volume: 1653

    Topics: Animals; Apoptosis; Brain Ischemia; Caspase 3; Cilostazol; Cognition Disorders; Disease Models, Anim

2016
The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum.
    Advances in experimental medicine and biology, 2010, Volume: 662

    Topics: Animals; Brain Ischemia; Cerebrum; Cilostazol; Male; Mice; Mice, Inbred C57BL; Organ Specificity; Ox

2010
Cilostazol, a type III phosphodiesterase inhibitor, reduces ischemia/reperfusion-induced spinal cord injury.
    The heart surgery forum, 2011, Volume: 14, Issue:3

    Topics: Animals; Cilostazol; Male; Phosphodiesterase 3 Inhibitors; Rats; Rats, Wistar; Reperfusion Injury; S

2011
Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels.
    Clinical and experimental pharmacology & physiology, 2011, Volume: 38, Issue:10

    Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Decanoic Acids; Disease Models, Animal; Drug Eva

2011
Are threshold levels of signal transduction required for the protective effect of cilostazol against cardiac ischaemia-reperfusion injury?
    Clinical and experimental pharmacology & physiology, 2011, Volume: 38, Issue:10

    Topics: Adenosine; Animals; Cardiotonic Agents; Cilostazol; Humans; Myocardial Infarction; Nitric Oxide; Pot

2011
Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Animals; Aspirin; Brain; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Immunohistochemistry;

2012
The protective effect of cilostazol on isolated rabbit femoral arteries under conditions of ischemia and reperfusion: the role of the nitric oxide pathway.
    Clinics (Sao Paulo, Brazil), 2012, Volume: 67, Issue:2

    Topics: Animals; Cilostazol; Disease Models, Animal; Femoral Artery; Hindlimb; Ischemia; Male; Nitric Oxide;

2012
Effects of cilostazol in kidney and skeletal striated muscle of Wistar rats submitted to acute ischemia and reperfusion of hind limbs.
    Acta cirurgica brasileira, 2012, Volume: 27, Issue:11

    Topics: Animals; Apoptosis; Caspase 3; Cilostazol; Disease Models, Animal; Hindlimb; In Situ Nick-End Labeli

2012
Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 308, Issue:3

    Topics: Animals; Blood-Brain Barrier; Blotting, Western; Brain Ischemia; Casein Kinase II; Chromosomes; Cilo

2004
Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice.
    Shock (Augusta, Ga.), 2006, Volume: 26, Issue:5

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aspirin; Cilostazol; Cyclic Nucleotide Phosphodiestera

2006
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.
    Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:5

    Topics: Adenosine; Administration, Oral; Animals; Atorvastatin; Body Weight; Cilostazol; Cyclic AMP-Dependen

2007
Selective type III phosphodiesterase inhibition prevents elevated compartment pressure after ischemia/reperfusion injury.
    The Journal of trauma, 1999, Volume: 46, Issue:5

    Topics: Animals; Anterior Compartment Syndrome; Cilostazol; Hindlimb; Muscle, Skeletal; Oxygen Consumption;

1999
Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 300, Issue:3

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain Infarction; Cilostazol; Cyc

2002